ATTR-CM

Dec 06, 2025

PiB-PET/CT detects subtypes in cardiac amyloidosis

Carbon-11 Pittsburgh compound B (C-11 PiB) PET/CT demonstrates robust capability for detecting cardiac amyloidosis and accurately differentiating its subtypes,…

Mar 17, 2025

Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

Expert and Community Perspectives on Attruby® (acoramidis)

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.